Praxis Precision Medicines to Advance Phase 2 PRAX-562 Study in Pediatric Patients with Developmental Encephalopathies and Epilepsy | MarketScreener
BOSTON, November 28, 2022 (GLOBE NEWSWIRE) — Praxis Precision MedicinesInc. (NASDAQ: PRACTICE), a clinical-stage biopharmaceutical company applying genetic insights to develop therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced plans to launch the PRACTICE-562 EMBOLD Phase 2 study for the treatment of pediatric patients with developmental and epileptic encephalopathies …